SELECTIVE INTRA-ARTERIAL CHEMOTHERAPY (IAC) IN TREATMENT AT CHILDREN WITH THE INTRAOCULAR RETYNOBLASTOMA
https://doi.org/10.21294/1814-4861-2018-17-1-64-71
Abstract
Treatment of intraocular retinoblastoma is challenging. It requires a multidisciplinary personalized approach that includes focal treatments, chemotherapy, surgery and radiotherapy. Today, the focus of therapy has shifted to eye preservation with the major aim to save the child’s life and to preserve the eyeball as a functioning organ of vision with minimal complications. One of the most promising therapy approaches is selective intra-arterial chemotherapy (IAC), by which a cytostatic agent is given directly into the eye. This treatment modality has been shown to provide survival benefit and improvement of quality of life, reducing toxicity and minimizing side effects.
About the Author
I. V. Pogrebnyakov
Clinical and Experimental Radiology Research Institute, Interventional Radiology Laboratory, N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Igor V. Pogrebnyakov - MD, Clinical and Experimental Radiology Research Institute, Interventional Radiology Laboratory, SPIN-code: 2533-4861.
24, Kashirskoe shosse, 115478-Moscow
References
1. Saakyan S.V. Retinoblastoma (clinic, diagnosis, treatment). Moscow, 2005. 200. [in Russian]
2. Kiss S., Leiderman Y., Mukai S. Diagnosis, Classification, and Treatment of Retinoblastoma. Int Ophthalmol Clin. 2008 Spring; 48 (2): 135–47. doi: 10.1097/IIO.0b013e3181693670.
3. Brovkina A.F., Astakhov Yu.S. Guide to Clinical Ophthalmology. Moscow, 2014. 960. [in Russian]
4. Brovkina A.F. Radiation therapy in the treatment of tumors of the organ of vision. Clinical Ophthalmology. 2003; 1: 15. [in Russian]
5. Saakyan S.V. Modern ideas about the structure of morbidity, etiopathogenesis, clinical course and treatment of retinoblastoma. Selected lectures on pediatric ophthalmology. Moscow, 2009: 83–101. [in Russian]
6. Kashkouli M.B., Beigi B. Late exposure after upper eyelid tarsoconjunctival flap for exposed porous orbital implant. Ophthalmic Surg Lasers Imaging. 2004 Nov-Dec; 35 (6): 499–502.
7. Iordanidou V., De Potter P. Porous polyethylene orbital implant in the pediatric population. Am J Ophthalmol. 2004 Sep; 138 (3): 425–9. doi: 10.1016/j.ajo.2004.04.062.
8. Nolan L.M., O’keefe M., Lanigan B. Hydroxyapatite orbital implant exposure in children. J AAPOS.2003; 7 (5): 345–8. doi: 10.1016/S1091853103001836.
9. Heimann H., Bechrakis N.E., Zepeda L.C., Coupland S.E., Hellmmich M., Foerster M.H. Exposure of orbital implants wrapped with polyester-urethane after enucleation for advanced retinoblastoma. Ophthal Plast Reconstr Surg. 2005; 21 (2): 123–8.
10. Chuah C.T., Chee S.P., Fong A.S., Por Y.M., Choo C.T., Luu C., Seah L.L. Integrated hydroxyapatite implant and non-integrated implants in nucleated Asian patients. Ann Acad Med. Singapore. 2004; 33 (4): 477–83.
11. Jung S.K., Cho W.K., Paik J.S., Yang S.W. Long–term surgical outcomes of porous polyethilene orbital implants: a review of 314 cases. Br J Ophthalmol. 2012 Apr; 96 (4): 494–8. doi: 10.1136/bjophthalmol-2011-300132.
12. Ushakova T.L., Belkina B.M., Polyakov V.G., Durnov L.A. Approaches to the treatment of locally advanced retinoblastoma in children. Achievements and prospects of ophthalmo oncology. Materials of the regional scientific-practical conference. Moscow. 2001; 156–158. [in Russian]
13. Filatova I.A. System of surgical rehabilitation of patients with anophthalmus and post-radial atrophy of orbital tissues. Russian Pediatric Ophthalmology. 2014; 4: 57. [in Russian]
14. Filatova I.A. Effectiveness of orbit plastics in post-ray atrophy at a later date after treatment with retinoblastoma. Russian national ophthalmologic forum, the 7th. Collection of scientific works. 2014; 2: 271–274. [in Russian]
15. Abramson D.H. The Evolution of Treatments for Retinoblastoma. Retina Todey. Nov/Dec 2010; 56–58.
16. Rivas-Perea P., Baker E., Hamerly G., Shaw B.F. Detection of leukocoria using a soft fusion of expert classifiers under non-clinical settings. BMC Ophthalmol. 2014 Sep 9; 14: 110. doi: 10.1186/1471-2415-14-110.
17. Rodriguez-Galindo C., Wilson M.W. Retinoblastoma. Springer Science+Business Media, LLC. 2010; 156.
18. Saakyan S.V., Tatskov R.A., Myakoshina E.B. Initial retinoblastoma: early diagnosis and combined organ-preserving treatment. Herald of Ophthalmology. 2012; 2: 55–59. [in Russian]
19. Ushakova T.L Modern approaches to the treatment of retinoblastoma. Herald of RONC im. N. N. Blokhina RAMN. 2011; 22 (2): 41–48. [in Russian]
20. Yarovoy A.A., Krivovyaz O.S., Ushakova T.L. Effectiveness of local treatment of multifocal retinoblastoma. Russian Pediatric Ophthalmology. 2014; 4: 63. [in Russian]
21. Yarovoy A.A., Ushakova T.L., Polyakov V.G. Results of local treatment of retinoblastoma with insufficient effectiveness of polychemotherapy. Ophthalmic Surgery. 2014; 1: 79–84. [in Russian]
22. Shields C.L., Palamar M., Sharma P., Ramasubramanian A., Leahey A., Meadows A.T., Shields J.A. Retinoblastoma Regression Patterns Following Chemoreduction and Adjuvant Therapy in 557 Tumors. Arch Ophthalmol. 2009; 127 (3): 282–290.
23. Rizzuti A.E., Dunkel I.J., Abramson D.H. The adverse events of chemotherapy for retinoblastoma: what are they? do we know? Arch Ophthalmol. 2008 Jun; 126 (6): 862–5. doi: 10.1001/archopht.126.6.862.
24. Jehanne M., Lumbroso-Le Rouic L., Davigoni A., Aerts I., Mercier G., Bours D., Desjardins L., Doz F. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatric Blood Cancer. 2009; 52: 637–43. doi: 10.1002/pbc.21898.
25. Bayer E., Robinson M.G., Kurcynski T.W. Unilateral retinoblastoma with acquired monosomy 7 and secondary acute myelomonosytic leukemia. Cancer Genet. Cytogenet. 1998; 105: 79–82.
26. Gunduz K., Gunalp I., Yalcindag N., Unal E., Tacyildiz N., Erden E., Geyik P.O. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology. 2004; 111: 1917–1924.
27. Gunduz K., Kose K., Kurt R.A., Suren E., Tacyildiz N., Dincaslan H., Ünal E., Erden E., Heper A.O. Retinoblastoma in Turkey: results from a tertiary care center in Ankara. J Pediatr Ophthalmol Strabismus. 2013 Sep-Oct; 50 (5): 296–303. doi: 10.3928/01913913-20130730-02.
28. Boughton B. Intravitreal Chemotherapy for Retinoblastoma: Promising but Controversial. Eyenet. 2013; 31–33.
29. Munier F.L., Gaillard M.C., Balmer A., Soliman S., Podilsky G., Moulin A.P., Beck-Popovic M. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to conditional indications. Br J Ophthalmol. 2012 Aug; 96 (8): 1078–83. doi: 10.1136/bjophthalmol-2011-301450.
30. Shields C.L., Manjandavida F.P., Arepalli S., Kaliki S., Lally S.E., Shields J.A. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: Preliminary results.JAMA Ophthalmol. 2014 Mar; 132 (3): 319–25. doi: 10.1001/jamaophthalmol.2013.7666.
31. Ghassemi F., Shields C.L., Ghadimi H., Khodabandeh A., Roohipoor R. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.JAMA Ophthalmol. 2014 Aug; 132 (8): 936–41. doi: 10.1001/jamaophthalmol.2014.414.
32. Brodie S.E., Munier F.L., Francis J.H., Marr B., Gobin Y.P., Abramson D.H. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Doc Ophthalmol. 2013; 126: 79–84. doi: 10.1007/s10633-012-9358-6.
33. Francis J.H., Schaiquevich P., Buitrago E., Del Sole M.J., Zapata G., Croxatto J.O., Marr B.P., Brodie S.E., Berra A., Chantada G.L., Abramson D.H. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: A preclinical and clinical study. Ophthalmology. 2014 Sep; 121 (9): 1810–7. doi: 10.1016/j.ophtha.2014.03.028.
34. Smith S.J., Smith B.D., Mohney B.G. Ocular side effects following intravitreal injection therapy for retinoblastoma: A systematic review. Br J Ophthalmol. 2014 Mar; 98 (3): 292–7. doi: 10.1136/bjophthalmol2013-303885.
35. Brodie S.E., Munier F.L., Francis J.H., Marr B., Gobin Y.P., Abramson D.H. Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Doc Ophthalmol. 2013 Feb; 126 (1): 79–84. doi: 10.1007/s10633-012-9358-6.
36. Smith S.J., Smith B.D., Mohney B.G. Ocular side effects following intravitreal injection therapy for retinoblastoma: A systematic review. Br J Ophthalmol. 2014 Mar; 98 (3): 292–7. doi: 10.1136/bjophthalmol2013-303885.
37. Shields C.L., Bianciotto C.G., Jabbour P., Ramasubramanian A., Lally S.E., Griffin G.C., Rosenwasser R., Shields J.A. Intra-arterial chemotherapy for retinoblastoma: Report No 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011 Nov; 129 (11): 1399–406. doi: 10.1001/archophthalmol.2011.150.
38. Reese A.B., Hyman G.A., Merriam G.R.Jr., Forrest A.W., Kligerman M.M. Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol. 1954 Apr; 53 (4): 505–13.
39. Hyman G.A., Reese A.B. Combination therapy of retinoblastoma with triethylene melamine and radiotherapy. J Am Med Assoc 1956; 162: 1368–73.
40. Kaneko A., Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003 Dec; 33 (12): 601–7.
41. Suzuki S., Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. nt J Clin Oncol. 2004 Feb; 9(1): 16.
42. Abramson D.H., Dunkel I.J., Brodie S.E., Kim J.W., Gobin Y.P. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008 Aug; 115 (8): 1398–404, 1404.e1. doi: 10.1016/j.ophtha.2007.12.014.
43. Gobin Y.P., Dunkel I.J., Marr B.P., Brodie S.E., Abramson D.H. Intra-arterial chemotherapy for the management of retinoblastoma: Fouryear experience.Arch Ophthalmol. 2011 Jun; 129 (6): 732–7. doi: 10.1001/archophthalmol.2011.5.
44. Laurie N.A., Gray J.K., Zhang J., Leggas M., Relling M., Egorin M., Stewart C., Dyer M.A. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res. 2005 Oct 15; 11 (20): 7569–78.
45. Suzuki S., Yamane T., Mohri M., Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011 Oct; 118 (10): 2081–7. doi: 10.1016/j.ophtha.2011.03.013.
46. Shields C.L., Say E.A., Pointdujour-Lim R., Cao C., Jabbour P.M., Shields J.A. Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy. J Fr Ophtalmol. 2015 Jun; 38 (6): 542–9. doi: 10.1016/j.jfo.2015.03.004.
47. Tuncer S., Sencer S., Kebudi R., Tanyildiz B., Cebeci Z., Aydin K. Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma: First 4-year experience from a single institution in Turkey.Acta Ophthalmol. 2016 Nov; 94 (7): e644e651. doi: 10.1111/aos.13077.
48. Michaels S.T., Abruzzo T.A., Augsburger J.J., Corrêa Z.M., Lane A., Geller J.I. Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience. J Pediatr Hematol Oncol. 2016 Jan; 38 (1): 65–9. doi: 10.1097/MPH.0000000000000471.
49. Abramson D.H., Marr B.P., Francis J.H., Dunkel I.J., Fabius A.W., Brodie S.E., Mondesire-Crump I., Gobin Y.P. Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (Tandem Therapy). PLoS One. 2016 Jun 3; 11 (6): e0156806. doi: 10.1371/journal.pone.0156806.
50. Chen M., Zhao J., Xia J., Liu Z., Jiang H., Shen G., Li H., Jiang Y., Zhang J. Intra-arterial chemotherapy as primary therapy for retinoblastoma in infants less than 3 months of age: A series of 10 case-studies. PLoS One. 2016 Aug 9; 11 (8): e0160873. doi: 10.1371/journal.pone.0160873.
51. Magan T., Khoo C.T., Jabbour P.M., Fuller D.G., Shields C.L. Intra-arterial chemotherapy for adult onset retinoblastoma in a 32-yearold man. J Pediatr Ophthalmol Strabismus. 2016 Jul 30; 53: e43–6. doi: 10.3928/01913913-20160722-01.
52. Shields C.L., Alset A.E., Say E.A., Caywood E., Jabbour P., Shields J.A. Retinoblastoma control with primary intra-arterial chemotherapy: Outcomes before and during the intravitreal chemotherapy era. J Pediatr Ophthalmol Strabismus. 2016 Sep 1; 53 (5): 275–84. doi: 10.3928/01913913-20160719-04.
53. Leal-Leal C.A., Asencio-López L., Higuera-Calleja J., BernalMoreno M., Bosch-Canto V., Chávez-Pacheco J., Isaac-Otero G., Beck-Popovic M. Globe salvage with intra-arterial topotecan-melphalan chemotherapy in children with a single eye. Rev Invest Clin. 2016; 68: 137–42.
Review
For citations:
Pogrebnyakov I.V. SELECTIVE INTRA-ARTERIAL CHEMOTHERAPY (IAC) IN TREATMENT AT CHILDREN WITH THE INTRAOCULAR RETYNOBLASTOMA. Siberian journal of oncology. 2018;17(1):64-71. (In Russ.) https://doi.org/10.21294/1814-4861-2018-17-1-64-71
Views:
2731
Email this article 
